Anon (1988). Acarbose. Scrip New Product Review no. 26. Richmond: P.J.B. Publications.Google Scholar

Aubell, R., Boehme, K. & Berchtold, P. (1982). One year acarbose treatment of diabetic outpatients. I Safety. II Efficacy. In Acarbose, effects on carbohydrate and fat metabolism, pp. 360–366 [Creutzfeldt, W., editor]. Amsterdam: Excerpta Medica.Google Scholar

Bischoff, H., Puls, W., Krause, H. P., Schmitt, H. & Thomas, G. (1985). Pharmacological properties of the novel glucosidase inhibitors BAY m 1099 (miglitol) and BAY o 1248. Diabetes Research and Clinical Practice Suppl. 1, 133.Google Scholar

Bowman, D. E. (1945). Amylase inhibitor of navy beans. Science 102, 358–359.CrossRefGoogle ScholarPubMed

Buonocore, V., Poerio, E. & Silano, V. (1981). The chemistry and biochemistry of α-amylase inhibitors. In Regulators of Intestinal Absorption in Obesity, Diabetes and Nutrition, vol. 1, pp. 87–101 [Berchtold, P., Cairella, M., Jacobelli, A. and Silano, V., editors]. Rome: Societa Editrice Universo.Google Scholar

Chrzaszcz, T. & Janicki, J. (1933). ‘Sisto-Amylase’, ein naturlicher Paralysator der Amylase. (‘Sisto-Amylase’, a natural inhibitor of amylase). Biochemische Zeitschrift 260, 354–368.Google Scholar

Clissold, S. P. & Edwards, C. (1988). Acarbose, a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35, 214–243.CrossRefGoogle ScholarPubMed

Clumeck, N. & Hermans, P. (1988). Antiviral drugs other than zidovudine and immunomodulating therapies in human immunodeficiency virus infection. An overview. American Journal of Medicine 85, 165–172.Google ScholarPubMed

Comai, K. & Sullivan, A. C. (1980). Antiobesity activity of pluronic L-101. International Journal of Obesity 4, 33–42.Google ScholarPubMed

Comai, K., Triscari, J. & Sullivan, A. C. (1978). Comparative effects of amphetamine and fenfluramine on lipid biosynthesis and absorption in the rat. Biochemical Pharmacology 27, 1987–1994.CrossRefGoogle ScholarPubMed

Creutzfeldt, W. (editor) (1982). In Acarbose, effects on carbohydrate and fat metabolism. Amsterdam: Excerpta Medica.Google Scholar

Creutzfeldt, W. (editor) (1988). In Acarbose for the Treatment of Diabetes Mellitus. Berlin: Springer-Verlag.CrossRefGoogle Scholar

Danzin, C. & Ehrhard, A. (1987). Time-dependent inhibition of sucrase and isomaltase from rat small intestine by castanospermine. Archives of Biochemistry and biophysics 257, 472–475.CrossRefGoogle ScholarPubMed

Dimitriadis, G., Hatziagelaki, E., Ladas, S., Linos, A. & Hillebrand, I. (1988). Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin dependent diabetes mellitus. European Journal of Clinical Investigation 18, 33–38.CrossRefGoogle ScholarPubMed

Eichler, H. G., Korn, A., Gasic, S., Pirson, W. & Businger, J. (1984). The effect of a new specific α-amylase inhibitor on post-prandial glucose and insulin excursions in normal subjects and type 2 (non-insulin-dependent) diabetic patients. Diabetalogia 26, 278–281.CrossRefGoogle ScholarPubMed

Goke, B., Fehmann, C., Folsch, U. R. & Creutzfeldt, W. (1984). Influence of a new absorbable inhibitor of α-glucosidase on the rate pancreas. Digestive Diseases and Sciences 29, 951.Google Scholar

Heinz, G., Komjati, M., Korn, A. & Waldhaeusl, W. (1989). Reduction of post-prandial blood glucose by the alpha-glucosidase inhibitor miglitol (BAY m 1099) in type II diabetes. European Journal of Clinical Pharmacology 37, 33–36.CrossRefGoogle Scholar

Hillebrand, I. & Boehme, K. (1982). Clinical studies on acarbose during 5 years. In Acarbose, effects on carbohydrate and fat metabolism, pp. 445–450. [Creutzfeldt, W., editor]. Amsterdam: Excerpta Medica.Google Scholar

Hillebrand, I., Boehme, K., Frank, G., Fink, H. & Berchtold, P. (1979 a). The effects of the α-glucosidase inhibitor Bay g 5421 (acarbose). on meal stimulated elevations of circulating glucose, insulin and triglyceride levels in man. Research in Experimental Medicine 175, 81–86.CrossRefGoogle ScholarPubMed

Hillebrand, I., Boehme, K., Frank, G., Fink, H. & Berchtold, P. (1979 b). The effects of the α-glucosidase inhibitor BAY g 5421 (acarbose) on postprandial blood glucose, serum insulin and triglyceride levels: dose time response relationships in man. Research in Experimental Medicine 175, 87–94.CrossRefGoogle ScholarPubMed

Hillebrand, I., Boehme, K., Graefe, K. H. & Wehling, K. (1986). The effect of new α-glucosidase inhibitors on meal stimulated increases in glucose and insulin levels in man. Klinische Wochenschrift 64, 393–396.CrossRefGoogle ScholarPubMed

Hillmann, R. J., Scott, M. & Gray, R. S. (1989). Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes. Diabetes Research 10, 81–84.Google Scholar

Holt, P. R., Thea, D., Yang, M. Y. & Kotler, D. P. (1988). Intestinal and metabolic responses to an alpha-glucosidase inhibitor in normal volunteers. Metabolism 37, 1163–1170.CrossRefGoogle Scholar

Homma, Y., Irie, N., Yano, Y., Nakaya, N. & Goto, Y. (1982). Changes in plasam lipoprotein levels during medication with a glucosidase hydrolase inhibitor (acarbose). Tokai Journal of Experimental and Clinical Medicine 7, 393–396.Google Scholar

Horii, S., Fukase, H., Matsuo, T., Kameda, Y., Asano, N. & Matsui, K. (1986). Synthesis and &-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. Journal of Medicinal Chemistry 29, 1038–1046.CrossRefGoogle ScholarPubMed

Jenkins, D. J. A. & Taylor, R. H. (1981). Significance of indigestible carbohydrates in the management of diabetes, hyperlipidaemia and obesity. In Regulators of Intestinal Absorption in Obesity, Diabetes and Nutrition, pp. 295–314 [Berchtold, P., Cairella, M., Jacobelli, A. and Silano, V., editors]. Rome: Societa Editrice Universo.Google Scholar

Jenkins, D. J. A. & Taylor, R. H. (1982). Acarbose: dosage and interactions with sugars, starch and fibre. In Acarbose, effects on carbohydrate and fat metabolism, pp. 86–96 [Creutzfeldt, W., editor]. Amsterdam: Excerpta Medica.Google Scholar

Jenkins, D. J. A., Taylor, R. H., Goff, D. V., Fielden, H., Misiewicz, J. J., Sarson, D. L., Bloom, S. R. & Alberti, K. G. M. (1981 a). Scope and specificity of acarbose in slowing carbohyrdrate absorption in man. Diabetes 30, 951–954.CrossRefGoogle Scholar

Jenkins, D. J. A., Wolever, T. M. S., Taylor, R. H., Barker, H. M., Fielden, H., Baldwin, J. M., Bowling, A. C., Newman, H. C., Jenkins, A. L. & Goff, D. V. (1981 b). Glycaemic index of foods: a physiological basis for carbohydrate exchange. American Journal of Clinical Nutrition 34, 362–366.CrossRefGoogle Scholar

Jenkins, D. J. A., Wolever, T. M. S., Taylor, R. H., Ghafari, H., Jenkins, A. L., Barker, H. M. & Jenkins, M. J. A. (1980). Rate of digestion of foods and post-prandial glycaemia in normal and diabetic subjects. British Medical Journal 281, 14–17.CrossRefGoogle Scholar

Joubert, P. H., Foukaridis, G. N. & Bopape, M. J. (1987). Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha glucosidase. European Journal of Clinical Pharmacology 31, 723–724.CrossRefGoogle ScholarPubMed

Katsilambros, N., Philippides, P., Toskas, A., Protopapas, J., Frangaki, D., Marangos, M., Siskoudis, P., Anastasopoulou, K., Xefteri, H. & Hillebrand, I. (1986). A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type 2 diabetics. Arzneimittelfoschugn 36, 1136–1138.Google ScholarPubMed

Kennedy, F. P. & Gerich, J. E. (1988). Alpha-glucosidase inhibition and timing of pre-prandial insulin in patients with insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice 4, 309–312.CrossRefGoogle Scholar

Kennedy, F. P., Miles, J. M., Heiling, V. & Gerich, J. E. (1987). The effect of two new α-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers. Clinical and Experimental Pharmacology and Physiology 14, 633–640.CrossRefGoogle ScholarPubMed

Kneen, E. & Sandstedt, R. M. (1943). An amylase inhibitor from certain cereals. Journal of the American Chemical Society 65, 1247.CrossRefGoogle Scholar

Kneen, E. & Sandstedt, R. M. (1946). Distribution and general properties of an amylase inhibitor in cereals. Archives of Biochemistry 9, 235–249.Google ScholarPubMed

Lembke, B., Foelsch, U. R. & Creutzfeldt, W. (1985). Effect of I-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro. Digestion 31, 109–116.Google Scholar

Madar, Z. (1989). Metabolic consequence of the alpha-glucosidase inhibitor BAY m 1099 given to non-diabetic and diabetic rats fed a high-carbohydrate diet. American Journal of Clinical Nutrition 49, 106–111.CrossRefGoogle Scholar

Müller, F. O. (1988). The pharmacokinetics of acarbose in humans. In Acarbose for the Treatment of Diabetes Mellitus, pp. 17–24 [Creutzfeldt, W., editor]. Berlin: Springer-Verlag.CrossRefGoogle Scholar

Müller, F. O. & Hillebrand, I. (1986). Acarbose (BAY g 5421) kinetics in healthy volunteers. Acat Pharmacologica et Toxicologica 59, Suppl. V. 303.Google Scholar

O'Dea, K. & Turton, J. (1985). Optimum effectiveness of intestinal α-glucosidase inhibitors: importance of uniform distribution through a meal. American Journal of Clinical Nutrition 41, 511–516.CrossRefGoogle ScholarPubMed

Puls, W. & Keup, U. (1973). Influence of an α-amylase inhibitor (BAY d 7791) on blood glucose, serum insuling and NEFA in starch loading tests in rats, dogs and man. Diabetologia 9, 97–101.CrossRefGoogle Scholar

Puls, W., Keup, U., Krause, H. P., O'Dea, K. & Sitt, R. (1981). Pharmacological significance of alpha-amylase inhibitors. In Regulators of Intestinal Absorption in Obesity, Diabetes and Nutrition, vol. 1, pp. 153–179 [Berchtold, P., Cairella, M., Jacobelli, A. and Silano, V., editors]. Rome: Societa Editrice Universo.Google Scholar

Puls, W., Keup, U., Krause, H. P. & Thomas, G. (1977 a). Glucosidase inhibition: a new approach to the treatment of carbohydrate dependent metabolic disorders. Diabetologia 13, 426.Google Scholar

Puls, W., Keup, U., Krause, H. P., Thomas, G. & Hoffmeister, F. (1977 b). Glucosidase inhibition: a new approach to the treatment of diabetes, obesity and hyperlipoproteinaemia. Nuturwissenschaften 64, 536.CrossRefGoogle Scholar

Puls, W., Krause, H. P., Muller, L., Schutt, H., Sitt, R., & Thomas, G. (1984). Inhibitors of the rate of carbohydrate and lipid absorption by the intestine. International Journal of Obesity 8, Suppl. 1, 181–190.Google ScholarPubMed

Radziuk, J., Kemmer, F., Berchtold, P. & Vranic, M. (1982). Quantitation of the effects of the α-glucosidase inhibitor acarbose on the hydrolysis and absorption of sucrose and hormone responses in man. In Acarbose, effects on carbohydrare and fat metabolism, pp. 113–122 [Creutzfeldt, W., editor]. Amsterdam: Excerpta Medica.Google Scholar

Ramsch, K. D., Wetzelsberger, N., Putter, J. & Maul, W. (1985). Pharmacokinetics and metabolism of the desoxynojirimycin derivatives BAY m 1099 and BAY o 1248. Diabetes Research and Clinical Practice Suppl. 1, 1199.Google Scholar

Rhinehart, B. L., Robinson, K. M., Liu, P. S., Payne, A. J., Wheatley, M. E. & Wagner, S. R. (1987 a). Inhibition of intestinal disaccharidases and suppression of blood glucose by a new α-glucohydrolase inhibitor-MDL 25,637. Journal of Pharmacology and Experimental Therapeutics 241, 915–920.Google ScholarPubMed

Rhinehart, B. L., Robinson, K. M., Payne, A. J., Wheatley, M. E., Fisher, J. L., Liu, P. S. & Cheng, W. (1987 b). Castanospermine blocks the hyperglycaemic response to carbohydrates in vivo: a result of intestinal disaccharidase inhibition. Life Sciences 41, 2325–2331.CrossRefGoogle ScholarPubMed

Samad, A. H., Willing, T. S., Alberti, K. G. & Taylor, R. (1988). Effects of Bay m 1099, a new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in non-insulin dependent diabetes mellitus over one month. Diabetes Care 11, 337–344.CrossRefGoogle Scholar

Schmidt, D. D., Frommer, W., Junge, B., Müller, L., Wingender, W., Truscheit, E. & Schafter, D. (1977). α-glucosidase inhibitors: new complex oligosaccharides of microbial orgin. Naturwissenschaften 64, 535–536.CrossRefGoogle Scholar

Schnack, C., Prager, R. J., Winkler, J., Klauser, R. M. & Schneider, B. G. (1989). Effects of 8-week alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 12, 537–543.CrossRefGoogle Scholar

Scott, A. R. & Tattersall, R. B. (1988). Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus. Diabetic Medicine 5, 42–46.CrossRefGoogle ScholarPubMed

Serrano-Rios, M., Saban, J., Navascues, I., Canizo, J. F. & Hillebrand, I. (1988). Effect of two new alpha-glucosidase inhibitors in insulin-dependent diabetic patients. Diabetes Research and Clinical Practice 4, 111–116.CrossRefGoogle ScholarPubMed

Sitt, R., Krause, H. P., Puls, W., Steinert, G. & Horstmann, H. (1980). Inhibition of cholesterol and triglyceride absorpition. VIIth International Symposium on Drugs Affecting Lipid Metabolism, p. 80. Milano: Fondazione G. Lorenzini.Google Scholar

Taylor, R. H., Barker, H. M., Bowey, E. A. & Canfield, J. E. (1986). Regulation of the absorption of the dietary carbohydrate in man by two new glucosidase inhibitors. Gut 27, 1471–1478.CrossRefGoogle Scholar

Taylor, R. H., Jenkins, D. J. A., Barker, H. M., Fielden, H., Goff, D. V., Misiewicz, J. J., Lee, D. A., Allen, B., McDonald, G. & Wallrabe, H. (1982 a). Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorpition. Diabetes Care 5, 92–96.CrossRefGoogle Scholar

Taylor, R. H., Jenkins, D. J. A., Goff, D. V., Bloom, S. R., Sarson, D. L., Misiewicz, J. J. & Alberti, K. M.G. M. (1982 b). Gut hormone response to carbohydrate with acarbose and guar. In Acarbose, effects on carbohydrate and fat metabolism, pp. 206–209 [Creutzfeldt, W., editor]. Amsterdam: Excerpta Medica.Google Scholar

Taylor, R. H., Jenkins, D. J. A., Goff, D. V., Nineham, R., Bloom, S. R. & Sarson, D. (1980). Enteroglucagon release stimulated by carbohydrate malabsorption: a clue to its physiological role? Gut 21, 449.Google Scholar

Truscheit, E., Frommer, W., Junge, B., Müller, L., Schmidt, D. D. & Wingender, W. (1981). Chemistry and Biochemistry of microbial α-glucosidase inhibitors. Angewandte Chemike 20, 744–761.Google Scholar

Truscheit, E., Hillebrand, I., Junge, B., Müller, L., Puls, W. & Schmidt, D. (1988). Microbial α-glucosidase inhibitors: chemistry, biochemistry and therapeutic potential. Progress in Clinical Biochemistry 7, 17–99.CrossRefGoogle Scholar

Tyms, A. S., Berrie, E. M., Ryder, T. A., Nash, R. J., Hegarty, M. P., Taylor, D. L., Mobberley, M. A., Davis, J. M., Bell, E. A., Jeffries, D. J., Taylor-Robinson, D. & Fellows, L. E. (1987). Castanospermine and other plant alkaloid inhibitors of glucosidase activity block the growth of HIV. Lancet ii, 1025–1026.CrossRefGoogle Scholar

Uttenthal, L. O., Ukponmwan, O. O., Wood, S. M., Ghiglione, M., Ghatei, M. A., Trayner, I. M. & Bloom, S. R. (1986). Long-term effects of intestinal alphaglucosidase inhibition on post-prandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics and sulphonylureas. Diabetic Medicine 3, 155–160.CrossRefGoogle ScholarPubMed

Uttenthal, L. O., Ukponmwan, O. O., Ghiglione, M., & Bloom, S. R. (1987). Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man. Digestive Diseases and Sciences 32, 139–144.CrossRefGoogle ScholarPubMed

Vertesy, L., Oeding, V., Bender, R., Nesemann, G., Sukatsch, D. & Zepf, K. (1981). Chemistry and biochemistry of a novel alpha-amylase inactivator HOE 467 from St. tendae. In Regulators of Intestinal Absorption in Obesity, Diabetes and Nutrition, vol. 2, pp. 269–274 [Berchtold, P., Cairella, M., Jacobelli, A., and Silano, V., editors]. Rome: Societa Editrice Universo.Google Scholar

Vierhapper, H., Bratusch-Marrain, P. & Waldhausl, W. (1981). Long term treatment of sulphonylurea-treated diabetics with the alpha-glucosidase inhibitor Bay g 5421 (acarbose). Diabetalogia 20, 586.CrossRefGoogle ScholarPubMed

William-Olsson, T. (1985). α-glucosidase inhibition in obesity. Acta Medica Scandinavica 706, Suppl., 1–39.Google Scholar

Yoshikuni, Y., Ezure, Y., Aoyagi, Y. & Enomoto, H. (1988). Inhibition of intestinal α-glucosidase and postprandial hyperglycaemia by N-substituted moranoline deriviatives. Journal of Pharmacobia-Dynamics 11, 356–362.CrossRefGoogle Scholar

Yoshikuni, Y., Ezure, Y., Seto, T., Mori, K., Watanabe, M. & Enomoto, H. (1989). Synthesis and α-glucosidase-inhibiting activity of a new alpha-glucosidase inhibitor, 4-0-alpha-D-glucopyranosylmoranoline and its N-substituted derivatives. Chemical and Pharmaceutical Bulletin 37, 106–109.CrossRefGoogle ScholarPubMed